Engineering microglia as intraoperative optical imaging agent vehicles potentially for fluorescence-guided surgery in

Ling Guo1, Xiaochen Zhang1, Runxiu Wei1

  • 1School of Pharmaceutical Sciences, Sun Yat-sen University, University Town, Guangzhou, 510006, P.R. China. wangcf6@mail.sysu.edu.cn fengmin@mail.sysu.edu.cn and Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-sen University, University Town, Guangzhou, 510006, P.R. China.

Biomaterials Science
|November 15, 2019
PubMed

Insights

Engineered microglial cells loaded with near-infrared dye show promise for precise brain tumor surgery. These DiDBV2-Fe cells cross the blood-brain barrier, clearly marking tumor borders for improved fluorescence-guided resection.

Area of Science:

  • Biomedical Engineering
  • Neuroscience
  • Oncology

Background:

  • Surgical resection is the primary treatment for gliomas, but maximizing tumor removal can cause neurological deficits.
  • Improving precision in brain tumor surgery through visual identification of tumor cells is crucial.

Purpose of the Study:

  • To engineer BV2 microglial cells as intraoperative optical imaging agents for fluorescence-guided brain tumor surgery.
  • To evaluate the efficacy of DiDBV2-Fe as an imaging agent for detecting brain tumors.

Main Methods:

  • BV2 microglial cells were stimulated with iron oxide nanoparticles and loaded with the near-infrared fluorescent dye DiD (DiDBV2-Fe).
  • The study assessed the impact of iron oxide activation on microglial cell markers and their ability to cross the blood-brain barrier (BBB).
  • In vivo experiments used an orthotopic glioblastoma mouse model to evaluate DiDBV2-Fe's tumor tropism and fluorescence imaging capabilities.

Main Results:

  • Iron oxide activation of BV2 cells inhibited immunosuppressive M2 markers and promoted BBB transport.
  • DiDBV2-Fe demonstrated strong tumor tropism in response to CCL2 secreted by U87MG tumor cells.
  • In vivo, DiDBV2-Fe efficiently crossed the BBB, with over 90% fluorescence detected in the brain, clearly demarcating tumor borders with a superior tumor-to-brain fluorescence ratio compared to 5-aminolevulinic acid.

Conclusions:

  • Engineered DiDBV2-Fe microglial cells show potential as an effective intraoperative imaging agent for brain tumors.
  • This approach can enhance the precision of fluorescence-guided tumor resections, potentially improving patient outcomes.
  • The prolonged fluorescence signal (4-24 h) is advantageous for complex surgical procedures.

Related Concept Videos